Literature DB >> 27589363

Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations.

Yudibeth Sixto-López1, Martiniano Bello1,2, Rolando Alberto Rodríguez-Fonseca1, Martha Cecilia Rosales-Hernández1,2, Marlet Martínez-Archundia1, José Antonio Gómez-Vidal3, José Correa-Basurto1.   

Abstract

Histone deacetylases (HDACs) are a family of proteins involved in the deacetylation of histones and other non-histones substrates. HDAC6 belongs to class II and shares similar biological functions with others of its class. Nevertheless, its three-dimensional structure that involves the catalytic site remains unknown for exploring the ligand recognition properties. Therefore, in this contribution, homology modeling, 100-ns-long Molecular Dynamics (MD) simulation and docking calculations were combined to explore the conformational complexity and binding properties of the catalytic domain 2 from HDAC6 (DD2-HDAC6), for which activity and affinity toward five different ligands have been reported. Clustering analysis allowed identifying the most populated conformers present during the MD simulation, which were used as starting models to perform docking calculations with five DD2-HDAC6 inhibitors: Cay10603 (CAY), Rocilinostat (RCT), Tubastatin A (TBA), Tubacin (TBC), and Nexturastat (NXT), and then were also submitted to 100-ns-long MD simulations. Docking calculations revealed that the five inhibitors bind at the DD2-HDAC6 binding site with the lowest binding free energy, the same binding mode is maintained along the 100-ns-long MD simulations. Overall, our results provide structural information about the molecular flexibility of apo and holo DD2-HDAC6 states as well as insight of the map of interactions between DD2-HDAC6 and five well-known DD2-HDAC6 inhibitors allowing structural details to guide the drug design. Finally, we highlight the importance of combining different theoretical approaches to provide suitable structural models for structure-based drug design.

Entities:  

Keywords:  HDAC6; PCA; molecular dynamics simulations; molecular modeling

Mesh:

Substances:

Year:  2016        PMID: 27589363     DOI: 10.1080/07391102.2016.1231084

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  5 in total

1.  Dihydropyrazole-Carbohydrazide Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6.

Authors:  Irving Balbuena-Rebolledo; Astrid M Rivera-Antonio; Yudibeth Sixto-López; José Correa-Basurto; Martha C Rosales-Hernández; Jessica Elena Mendieta-Wejebe; Francisco J Martínez-Martínez; Ivonne María Olivares-Corichi; José Rubén García-Sánchez; Juan Alberto Guevara-Salazar; Martiniano Bello; Itzia I Padilla-Martínez
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-31

2.  Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.

Authors:  Yudibeth Sixto-López; Marlet Martínez-Archundia
Journal:  J Comput Chem       Date:  2021-03-13       Impact factor: 3.672

Review 3.  HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

Authors:  Hélène Losson; Michael Schnekenburger; Mario Dicato; Marc Diederich
Journal:  Cancers (Basel)       Date:  2020-01-29       Impact factor: 6.639

4.  Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population.

Authors:  Yudibeth Sixto-López; José Correa-Basurto; Martiniano Bello; Bruno Landeros-Rivera; Jose Antonio Garzón-Tiznado; Sarita Montaño
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

Review 5.  Molecular Structure, Binding Affinity, and Biological Activity in the Epigenome.

Authors:  Balázs Zoltán Zsidó; Csaba Hetényi
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.